Precision Life Sciences Group

Executive Summary

Precision Life Sciences Group is a Nashville-based biotechnology company developing next-generation immunotherapies for cancer. Its proprietary Stem-to-T-Cell program engineers hematopoietic stem cells to continuously produce cancer-targeting T cells, potentially offering a durable, off-the-shelf therapy for solid tumors. The company also holds a portfolio of clinical-stage, patient-specific dendritic cell vaccines. In 2026, Precision Life Sciences is expected to report initial Phase 1 data from its lead Stem-to-T-Cell candidate, which could validate the platform's feasibility and safety. Additionally, the company may file an Investigational New Drug (IND) application for a second indication or begin a partnership to support manufacturing scale-up. While early-stage, the unique approach of generating a sustained T-cell supply addresses key limitations of current cell therapies, such as tumor relapse and manufacturing complexity. Success in early trials could position Precision Life Sciences as a leader in next-generation cell therapy.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1 data from lead Stem-to-T-Cell program45% success
• Q4 2026IND filing for second indication60% success
• TBDPartnership or licensing deal for manufacturing or distribution40% success